IP Library Granted Patent US 8,779,191
Granted Patent B2
US 8,779,191 · App. 12/973,453 · Granted Jul 15, 2014

Methods and compositions for preparing lisdexamfetamine and salts thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,779,191
App. No.
12/973,453
Granted
Jul 15, 2014
Kind
B2
Abstract

The invention provides methods and compositions for preparing lisdexamfetamine and salts thereof. More particularly, the invention provides, for example, methods of preparing lisdexamfetamine from D-amphetamine.

Claims (23)

1. A method of preparing a lysine-amphetamine compound, comprising admixing an amphetamine compound of Formula I with a lysine compound of Formula II to provide a lysine-amphetamine compound of Formula III, wherein Formula I is represented by:

or a salt thereof;

Formula II is represented by:

wherein Z is

 and R 3 is hydrogen; and

Formula III is represented by:

and crystallizing said lysine-amphetamine compound of Formula III from a mixture comprising (i) at least one of a C 1 -C 4 aliphatic alcohol, C 1 -C 4 aliphatic carboxylic acid, aliphatic tertiary amine, or water, and (ii) (C 1 -C 4 alkyl)—CO 2 —(C 1 -C 4 alkyl), to provide a purified lysine-amphetamine compound of Formula III.

2. The method of claim 1 , wherein Formula I is

having a purity of at least 90% (w/w), Formula II is

and Formula III is

3. The method of claim 1 , wherein Formula I has a purity of at least 97% (w/w).

4. The method of claim 1 , comprising crystallizing said lysine-amphetamine compound of Formula III from a mixture comprising (i) at least 20% (v/v) methanol, and (ii) at least 20% (v/v) isopropyl acetate, to provide a purified lysine-amphetamine compound of Formula III.

5. The method of claim 1 , comprising re-crystallizing said purified lysine-amphetamine compound of Formula III from a mixture comprising at least one of a C 1 -C 4 aliphatic alcohol, C 1 -C 4 aliphatic carboxylic acid, aliphatic tertiary amine, or water, to provide a high-purity lysine-amphetamine compound of Formula III.

6. The method of claim 1 , wherein the purified lysine-amphetamine compound of Formula III has a purity of at least 99% (w/w).

7. The method of claim 5 , wherein the high-purity lysine-amphetamine compound of Formula III has a purity of at least 99.9% (w/w).

8. The method of claim 1 , further comprising admixing said lysine-amphetamine compound of Formula II, a hydrogenation catalyst, and a hydrogen source to provide a lysine-amphetamine compound of Formula IV, wherein the compound of Formula IV is represented by:

9. The method of claim 8 , wherein the hydrogenation catalyst comprises palladium on carbon, and the hydrogen source is hydrogen gas or ammonium formate.

10. The method of claim 8 , further comprising admixing said lysine-amphetamine compound of Formula IV and an acid to provide an acid salt of said lysine-amphetamine compound of Formula IV.

11. The method of claim 10 , wherein the acid is methanesulfonic acid.

12. The method of claim 10 , further comprising admixing a lysine compound of Formula V with a carboxylic acid-activating agent to provide a lysine compound of Formula II; wherein the lysine compound of Formula V is represented by:

13. The method of claim 1 , wherein the purified lysine-amphetamine compound of Formula III contains less than 0.6% (w/w) N-hydroxysuccinimide.

14. The method of claim 1 wherein the admixing of the amphetamine compound of Formula I with the lysine compound of Formula II to provide the lysine-amphetamine compound of Formula III is done with no additional base.

15. The method of claim 14 wherein the admixing of the amphetamine compound of Formula I with the lysine compound of Formula II to provide the lysine-amphetamine compound of Formula III is done with no diisopropylethylamine.

Assignments (7)
RELEASE OF FIRST LIEN SECURITY INTEREST IN PATENTS Recorded Mar 6, 2025
From: ROYAL BANK OF CANADA
To: CAMBREX CHARLES CITY, INC.; AVISTA PHARMA SOLUTIONS, INC.; SNAPDRAGON CHEMISTRY, INC.
Reel/Frame 070438/0333 →
RELEASE OF SECOND LIEN SECURITY INTEREST IN PATENTS Recorded Dec 7, 2020
From: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
To: AVISTA PHARMA SOLUTIONS, INC.
Reel/Frame 054630/0307 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Dec 4, 2019
From: CAMBREX CHARLES CITY, INC.; AVISTA PHARMA SOLUTIONS, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 051196/0080 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded Dec 4, 2019
From: AVISTA PHARMA SOLUTIONS, INC.; CAMBREX CHARLES CITY, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 051283/0877 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS Recorded Dec 4, 2019
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: CAMBREX CHARLES CITY, INC.
Reel/Frame 051283/0903 →
SECURITY INTEREST Recorded Jan 3, 2019
From: CAMBREX CHARLES CITY, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047895/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2011
From: BAUER, MICHAEL J.; CALLEN, GARY RICHARD; HUMPHREY, JUDI CHRISTINE; JOHNSON, TODD JEFFREY; SCHIESHER, MATTHEW WENDELL
To: CAMBREX CHARLES CITY, INC.
Reel/Frame 026148/0179 →